Organization (Academic)
William Marsh Rice University
ClinicalTrials.gov lists William Marsh Rice University as lead sponsor of 17 trials. It has 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Thiago602, via Wikimedia Commons, CC BY-SA 4.0. Shown to identify the organization; it may be a registered trademark.
This page covers William Marsh Rice University: 17 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (29)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Uterine Cervical Neoplasms | 5 |
| Pre-Eclampsia | 4 |
| Uterine Cervical Dysplasia | 4 |
| Head and Neck Neoplasms | 3 |
| Barrett Esophagus | 2 |
Showing 5 of 29 disease areas.
Trials by start year as sponsor or collaborator (18)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 3 |
| 2024 | 2 |
| 2023 | 2 |
| 2022 | 4 |
| 2021 | 4 |
| 2020 | 3 |
| 2019 | 5 |
| 2018 | 1 |
| 2017 | 5 |
Showing 10 of 18 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Exercise | 1 |
| Semaglutide | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 2 hit target (n=2) | 2 of 4 on time (n=4) |
Journals published in (141)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Brain, behavior, and immunity | 7 |
| Proceedings of the National Academy of Sciences of the United States of America | 5 |
| The New England journal of medicine | 5 |
| Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 4 |
| Diabetes care | 4 |
Showing 5 of 141 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 615 | 90 | 2025-12-30 |
Financing and grant events (366)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-17 | NIH grant | 543,698 | Reporter |
| 2025-08-28 | NIH grant | 263,274 | Reporter |
| 2025-08-26 | NIH grant | 1,300,000 | Reporter |
| 2025-08-19 | NIH grant | 226,702 | Reporter |
| 2025-08-19 | NIH grant | 261,099 | Reporter |
Showing 5 of 366 events.
Organization relationships (4)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Harris Health System | Co sponsors trial with | 2 |
| University of Malawi | Co sponsors trial with | 2 |
| Anandasabapathy, Sharmila, M.D. | Co sponsors trial with | 2 |
| The University of Texas System | Co sponsors trial with | 1 |
Latest dated events (1,032)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-04-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 1,032 events.
Biomarker capability evidence (50)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| FES | Trial sponsor | Named in trial inclusion criteria |
| HGD | Trial collaborator | Named in trial inclusion criteria |
| PYCARD | Trial collaborator | Named in trial inclusion criteria |
| PYCARD | Trial collaborator | Named in trial inclusion criteria |
| SLC12A3 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 50 evidence rows.
Biomarkers this organization publishes on (188)
Shown in this order: most publications first.
Showing 5 of 188 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.